Scholars Central

Research articlePublished 3 May 2021

Evaluation of Contrast-Enhanced Magnetic Resonance Imaging and Spectroscopy as Diagnostic Tests to Differentiate Tumour Progression versus Post-Treatment Changes in Adult Gliomas and Their Correlation with Single-Photon Emission Computed Tomography - A Cross-Sectional Study from a Tertiary Care Centre in Pune, India

Authors: Ashima Chander, Peeyush Dhagat, Debraj Sen, Harkirat Singh

Journal of Evidence-Based Medicine and Healthcare

Volume 8 · Issue 18 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

BACKGROUND The differentiation of tumour progression from treatment-induced changes is critical in evaluating response to therapy among patients with gliomas. Although conventional magnetic resonance imaging (MRI) is invaluable in the overall assessment of such lesions, it is often difficult to differentiate between these two entities. We wanted to evaluate the role of contrast-enhanced MRI (CE MRI) and magnetic resonance spectroscopy (MRS) and correlation with 99 m Tc Sestamibi single-photon emission tomography (SPECT) in differentiating tumour progression from post-therapy changes in patients with glioma. METHODS This was a cross-sectional study. Being a rare disease, all adult patients (25 in number) with brain glioma reporting to the hospital for over a period of 12 months were included in the study. CE MRI, MRS and SPECT were performed at three months, six months and 12 months’ post-surgery and radiotherapy. The ratios for choline (Cho) / N-acetyl aspartate (NAA) and choline (Cho) creatine (Cr) were obtained from the areas suspicious for tumour progression on CE MRI and were correlated with the presence or absence of uptake on SPECT. These findings were correlated with the patients’ clinical course and tumour histopathology. RESULTS Both choline (Cho) / N-acetyl aspartate (NAA) and choline (Cho) / creatine (Cr) ratios had high detection rates for tumour progression when cut-off values of > 1.75 were used. For the Cho / NAA ratio, the sensitivity and specificity were 93.7 % and 100 %, respectively. The sensitivity and specificity for the Cho / Cr ratio were 81.3 % and 88.9 %, respectively. The sensitivity and specificity of 99 m Tc Sestamibi SPECT were 87.5 % and 100 %, respectively. CONCLUSIONS MRS and SPECT have high sensitivity and specificity for diagnosing tumour progression and must be used in conjunction with conventional CE MRI in the posttherapy setting.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Evidence-Based Medicine and Healthcare.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Evidence-Based Medicine and Healthcare
  • SubjectNursing & Healthcare
  • BylineArticles whose byline prints “Ashima Chander”
  • BylineArticles whose byline prints “Peeyush Dhagat”
  • BylineArticles whose byline prints “Debraj Sen”
  • BylineArticles whose byline prints “Harkirat Singh”